Monday, April 29, 2024
4/29/2024
DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the third leading cause of cancer-related death in the U.S. Although advances in CRC screening, surgical therapies and medical management have improved clinical outcomes, there still is a major need to develop better medical therapies for CRC, particularly among those with advanced local or metastatic disease. The 5-year survival rate of victims with stage IV disease is a dismal 5%. There is increasing evidence that most solid tumors, including CRC, have a subpopulation of tumor-initiating cells termed tumor stem cells (TSCs). Epithelial-mesenchymal transition (EMT) is a key feature in cancer invasion and metastasis and is linked to a TSC phenotype in CRC. The COARE team has demonstrated that the tumor stem cell marker DCLK1 is significantly upregulated in CRC and is a central regulator of key oncogenic pathways and EMT. Recent studies have definitively confirmed DCLK1's TSC status in the Apcmin/+ model of intestinal neoplasia. COARE's pre-clinical experimental data shows that therapeutic targeting of cells that overexpress DCLK1 arrests tumor growth in xenografts and reduces the size and number of adenomas in Apcmin/+ mice. DCLK1 signaling inhibition triggers the induction/activation of several critical endogenous tumor-suppressor pathways within the tumor, which in turn regulate oncogenic pathways and processes and EMT-related transcription factors. DCLK1 is a unique TSC marker because it contains an extracellular C-terminal domain. Antibody-drug conjugates (ADCs) allow the specific targeting of tumor cell-surface expressed antigens with cytotoxins, with the potential benefits of enhanced efficacy and reduced off-target toxicity. COARE's CBT-3112 is a Paclitaxel-based ADC targeting the DCLK1 TSC/CTC antigen in CRC with the potential to improve outcomes in locally advanced/metastatic CRC. We will pursue three Specific Aims. Aim 1: Demonstrate that CBT-3112 will effectively deliver a cytotoxic payload to CRC cells resulting in cell death. Aim 2: Demonstrate that CBT-3112 will suppress tumor growth in TSC-derived tumor isografts. Aim 3: Demonstrate that CBT-3112 will suppress tumor growth in xenograft models of CRC with and without 5-fluorouracil and prevent in vivo metastasis. Test of Feasibility: CBT-3112 should induce cell death and inhibit proliferation comparable to Paclitaxel (PTX) alone. Additionally, it should significantly inhibit cell invasiveness and demonstrate internalization of PTX. In TSC isografts, CBT-3112 treatment should precipitate a significant reduction (>50%) in tumor growth and >40% induction of tumor suppressors and loss of downstream oncogenic signaling compared to controls. In the tumor xenografts, CBT- 3112 should significantly reduce tumor volume alone, sensitize tumors to 5-fluorouracil (5-FU), and prevent engraftment of metastatic CRC cells in an in vivo metastasis assay. Phase I success will lead to a Phase II project focused on humanizing DCLK1 mAb, completing detailed pharmacokinetics and in vivo toxicity analyses, and preparing for IND/clinical trial work to set th stage for ultimate commercialization.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
